Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
  • A61K36/062—Ascomycota
  • A61K36/064—Saccharomycetales, e.g. baker's yeast
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/42—Cucurbitaceae (Cucumber family)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
  • A61K36/534—Mentha (mint)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/55—Linaceae (Flax family), e.g. Linum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/82—Theaceae (Tea family), e.g. camellia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/044—Suspensions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/06—Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/06—Emulsions
  • A61K8/066—Multiple emulsions, e.g. water-in-oil-in-water
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9728—Fungi, e.g. yeasts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9789—Magnoliopsida [dicotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9794—Liliopsida [monocotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/18—Antioxidants, e.g. antiradicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• the present invention relates to the cosmetic use of an active ingredient derived from
• the invention also relates to anti-aging compositions comprising at least one active ingredient derived from Lin acting on specific markers of the popular dermis, and to a process for obtaining an active ingredient derived from Lin acting on the dermis. popular and obtained active ingredient.
• the objective of the present invention is to provide products capable of effectively fighting against skin aging, to help rejuvenate and revitalize the skin by considering the aspects of aging of the skin on the different skin layers.
• the skin consists of two tissues closely connected to each other: the epidermis on the surface, and the underlying dermis, in which we distinguish the popular dermis, adjacent to the dermal-epidermal junction, rich in fibroblasts, and the reticular dermis.
• the dermis constitutes the solid support of the skin. It is composed of fibroblasts and a microfibrary network, the extracellular matrix, rich in collagens, el ⁇ stine, glycoproteins and proteoglycans that provide support, extensibility and resistance.
• the popular dermis derives its name from its papillae surface, which form projections alternating with epidermal prolongations. It has a very fine fibrous structure, rich in cells, blood capillaries, nerve fibers and tactile corpuscles.
• the popular dermis notably contains oxytalan fibers which form a perpendicular network which seems anchored in the basement membrane. These fibers play an important role in the mechanical strength of the skin. An increase in the synthesis of these fibers makes it possible to reinforce the perpendicular network and thus to consolidate the mechanical strength of the skin.
• Collagen XVI is expressed both by keratinocytes and fibroblasts of the dermis. It contributes to the structural integrity of the popular dermis area. An increase in collagen synthesis XVI contributes to improving the structural integrity of the dermis.
• the extracellular matrix With age and external aggressions, the extracellular matrix is disorganized and impoverished in components: the skin becomes thinner, more fragile, drier and loses its elasticity, which causes the appearance of wrinkles, the loss brightness of the complexion and sagging skin.
• the present invention aims to act both on the thickness, elasticity and structural organization of the dermis popular, using at least one active ingredient derived from Lin, able to act on the synthesis of at least one fiber molecule specific for the popular dermis, for the preparation of a cosmetic and / or dermopharmaceutical composition intended to combat cutaneous aging.
• the present invention proposes to use at least one active principle derived from Lin, capable of acting on the synthesis of molecules specific to the popular dermis, in particular collagen XVI and / or oxytalan fibers.
• the active ingredient according to the invention may also act on the synthesis of other collagens of the popular dermis: collagen I, collagen VI and collagen XII, as well as on the synthesis of fibrinin in the popular dermis.
• the use according to the present invention makes it possible to combat cutaneous aging by acting on the popular dermis, in particular:
• oxytalan fibers a fiber specific for the popular dermis, which plays an important role in the mechanical strength and elasticity of the skin.
• the use according to the present invention may also make it possible: to increase the density of the dermis by synthesis of collagens I, VI and XII, and / or
• the use of at least one active ingredient derived from Lin according to the invention makes it possible to combat the appearance of wrinkles, the loss of luminosity of the complexion and / or the sagging skin associated with the aging of the skin.
• the active ingredient derived from Lin capable of acting on the dermis that is popular according to the present invention is an active ingredient obtained by a process comprising at least one hydrolysis.
• the active ingredient derived from Lin capable of acting on the dermis according to the invention is intended to be incorporated into cosmetic and / or dermopharmaceutical compositions.
• the cosmetic composition according to the invention may contain from 0.01 to 20% of at least one active ingredient derived from Lin capable of acting on the dermis.
• the administration of a cosmetic composition containing at least one active ingredient derived from Lin according to the invention, capable of acting on the popular dermis, is preferably carried out topically.
• composition according to the invention may be in the form of creams, oil-in-water emulsions, water-in-oil or multiple emulsions, solutions, suspensions or powders.
• the invention also relates to a process for obtaining an active ingredient derived from Lin capable of acting on the dermis, as well as the active ingredient obtained.
• the active ingredient derived from Lin capable of acting on the popular dermis which is useful according to the invention, can be obtained by a process comprising at least one hydrolysis. Preferably, it is obtained by a process comprising the following steps:
• “Flax” is understood to mean flaxseed of the Linum usitatissimum variety, reduced to powder form, in the form of flour or semolina, or flaxseed meal of the Linum usitatissimum variety obtained after extraction of the oily part. by pressing the seeds.
• the solids content is measured by passing the oven at 105 ° C. in the presence of sand of a sample of initial weight given until a constant weight is obtained.
• the solids content of an active ingredient derived from Lin according to the invention is between 5 and 200 g / l, more particularly between 15 and 60 g / l. 2-2 / pH measurement:
• the pH measured by the potentiometric method at room temperature leads to values between 3 and 7, more particularly between 3 and 5.
• the total protein content is determined by the LOWRY method.
• the level of proteins of an active principle derived from Lin according to the invention is between 1 and 65 g / l, more particularly between 3 and 20 g / l. 2-4 / Characterization of the protein fraction
• FPLC Fast Protein Liquid Chromatography
• the chromatogram shows that an active ingredient derived from Lin according to the invention is mainly composed of peptides with a molecular weight of less than 5000 Daltons. 2-5 / Determination of total sugar content
• the total sugar content of an active principle derived from Lin according to the invention is between 2 and 100 g / l, preferably between 5 and 30 g / l.
• the characterization of the monomeric sugars of an active principle derived from Lin according to the invention is carried out by high performance liquid chromatography (HPLC).
• an active ingredient derived from Lin according to the invention is composed, in descending order, of mannose, glucose, xylose and rhamnose.
• its carbohydrate fraction comprises at least 50% of mannose.
• Uronic acids form furan derivatives, by cycloaddition under the action of strong mineral acids.
• the furan derivatives thus formed are capable of condensing with different reagents by forming characteristic coloring complexes: the chromophores, product of the reaction, of variable color depending on the nature of the ose.
• Linen according to the invention is produced by high performance liquid chromatography.
• the chromatogram obtained shows the presence of about 74% of monosaccharides with a molecular mass of less than 180 Da, about 17% of oligosaccharides with a molar mass of between 180 and 2500 Da and about 9% of polysaccharides with a molar mass greater than 5000 Da. .
• the objective of this study is to evaluate the effect of an active ingredient derived from Lin according to the invention on the expression of mRNAs (messenger ribonucleic acids) encoding collagen I on aged fibroblasts derived from popular dermas in comparison with young fibroblasts from popular dermes.
• mRNAs messenger ribonucleic acids
• PCk Polymerase Chain Amplification
• the cells are cultured in the presence of an active ingredient derived from Lin according to the invention at 1%. Untreated cells that serve as a control are also preserved.
• RNAs are reverse-transcripts and DNAs (Acid
• the objective of this study is to evaluate the effect of an active ingredient derived from Lin according to the invention on the synthesis of collagen I on young and aged fibroblasts from popular dermas.
• the ELISA assay is performed with the following means:
• the active ingredient according to the invention derived from Lin acts by increasing the synthesis of collagen I in cultures of young human fibroblasts from popular dermas.
• the active ingredient according to the invention derived from Lin also acts by increasing the synthesis of collagen I in aged human fibroblast cultures derived from popular dermas.
• the objective of this study is to evaluate the effect of an active ingredient derived from Lin according to the invention on the expression of mRNAs encoding collagen VI on aged fibroblasts derived from popular dermas in comparison with young fibroblasts from of popular dermes.
• RNAs are reverse-transcripts and DNAs (Acid
• Deoxyribonucleic acid obtained are analyzed by quantitative PCR.
• the objective of this study is to evaluate the effect of an active ingredient derived from Lin according to the invention on the expression of mRNA encoding collagen XII on aged fibroblasts derived from popular dermas in comparison with young human fibroblasts from popular dermes.
• RNAs are reverse-transcripts and DNAs (Acid
• Deoxyribonucleic acid obtained are analyzed by quantitative PCR.
• the objective of this study is to evaluate the effect of an active ingredient derived from Lin according to the invention on the expression of mRNAs encoding collagen XVI on aged fibroblasts derived from popular dermas in comparison with young human fibroblasts from of popular dermes.
• RNAs are reverse-transcripts and DNAs (Acid
• Deoxyribonucleic acid obtained are analyzed by quantitative PCk.
• Fibrillin I is a glycoprotein essential in the formation of elastic fibers present in oxytalan fibers.
• the objective of this study is to evaluate the effect of an active ingredient derived from flax according to the invention on the expression of mRNAs encoding fibrillin I on aged fibroblasts derived from popular dermas in comparison with young human fibroblasts from popular dermes.
• the study is carried out by PCR (Polymerase Chain Amplification) according to the operating protocol below.
• the young and aged human fibroblasts are inoculated and incubated.
• the cells are cultured in the presence of an active ingredient derived from Lin according to the invention at 1%. Untreated cells that serve as a control are also preserved.
• RNAs are reverse-transcripts and DNAs (Acid
• Deoxyribonucleic acid obtained are analyzed by quantitative PCR.
• the objective of this study is to show the in vivo efficacy of the active ingredient from Lin according to the invention formulated at 4% emulsion versus placebo on the biomechanical properties of the skin, at the level of the lower face.
• the study is conducted on 18 healthy female volunteers. The measurements are made at the level of the lower face using a Cutometer: the skin is sucked by a constant vacuum probe for a constant duration. The penetration depth of the skin in the probe is measured by two optical prisms, which allows to obtain curves from which it is possible to calculate various characteristic parameters of the mechanical properties of the skin. Among these parameters, the present study consists in observing the following parameters:
• two symmetrical cutaneous zones are determined at the level of the lower face and the biomechanical properties of the skin are measured on these two zones.
• the active ingredient derived from Lin according to the invention makes it possible to increase the skin firmness by 10%, the cutaneous tonicity by 14% and the elasticity by 8%. In addition, it is found that twice-daily applications of the active ingredient derived from Lin according to the invention for 56 days make it possible to reduce skin fatigue by 16% compared with placebo.
• the present invention also covers cosmetic and / or dermopharmaceutical compositions including at least one active ingredient derived from Lin capable of acting on the dermis popular according to the present invention in different galenic forms, adapted for topical administration to the skin.
• compositions may especially be in the form of creams, oil-in-water emulsions, water-in-oil emulsions, multiple emulsions, solutions, suspensions or powders. They can be more or less fluid and have the appearance of a cream, a lotion, a milk, a serum, an ointment, a gel, a paste or a foam, or in solid form.
• compositions contain between 0.01 and 20% by weight of active principle (s) derived from Lin capable (s) act on the dermis popular according to the present invention.
• composition examples are obtained by mixing the various components. The quantities indicated are given as a percentage of weight. 4.1
• Cetearyl alcohol / Cetearyl glucoside 2.0%

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Chemical & Material Sciences (AREA)
• Botany (AREA)
• Biotechnology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Alternative & Traditional Medicine (AREA)
• Medical Informatics (AREA)
• Birds (AREA)
• Dermatology (AREA)
• Dispersion Chemistry (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Cosmetics (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=38134128

Family Applications (2)

Family Applications After (1)

Country Status (3)

Families Citing this family (16)

Citations (6)

Family Cites Families (21)

• 2006
  • 2006-10-05 FR FR0654098A patent/FR2906719A1/fr not_active Withdrawn
• 2007
  • 2007-10-05 WO PCT/FR2007/052086 patent/WO2008043944A2/fr not_active Ceased
  • 2007-10-05 EP EP07858517A patent/EP2073787A2/de not_active Ceased
  • 2007-10-05 EP EP20173146.0A patent/EP3744311A1/de not_active Withdrawn

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events